HEAL Initiative: Integrated Approach to Pain and Opioid Use in Hemodialysis Patients: The Hemodialysis Opioid Prescription Effort (HOPE) Consortium - Clinical Centers (U01 Clinical Trial Required)

The summary for the HEAL Initiative: Integrated Approach to Pain and Opioid Use in Hemodialysis Patients: The Hemodialysis Opioid Prescription Effort (HOPE) Consortium - Clinical Centers (U01 Clinical Trial Required) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
HEAL Initiative: Integrated Approach to Pain and Opioid Use in Hemodialysis Patients: The Hemodialysis Opioid Prescription Effort (HOPE) Consortium - Clinical Centers (U01 Clinical Trial Required): Pain is a common problem in Medicare End-Stage Renal Disease (ESRD) Hemodialysis (HD) patients, but its prevalence varies widely by geography, dialysis unit, and possibly, ethnicity. Pain has been linked to decreased quality of life, lack of social support, depressed mood and other mental health disorders. Chronic opioid prescription has been identified in approximately 20% of US ESRD HD patients, far higher than in Medicare comparison populations. Opioid doses prescribed to HD patients exceed Centers for Disease Control and Prevention (CDC) recommendations. Prescription and dose level have been associated with increased hospitalizations and mortality in this population. Interventions including behavioral modification techniques such as Cognitive Behavioral/Group Therapy and social media platforms for sharing information and enhancing social support have not been employed to reduce perception of pain and the rate of opioid prescription, dose and opioid use, as well as addressing comorbid related issues such as depression, and anxiety in the HD population.Medical interventions such as use of naloxone and buprenorphine have not been evaluated by randomized controlled trials in HD patients who use opioids. The ESRD population, because of its continuous longitudinal participation in monitored treatment and the availability of data resources is an ideal population in which to launch and monitor interventions. The Hemodialysis Opioid Prescription Effort (HOPE) consortium composed of 5 or 6 Clinical Centers (CCs)and a Scientific and Data Research Center (SDRC) will develop an intervention to simultaneously address the problem of pain and opioid use in US HD populations by a) initiating multipronged pain treatment tailored individually to each patient, without opioids, and b) using buprenorphine and other novel agents to reduce dependence on opioids in affected patients.
Federal Grant Title: HEAL Initiative: Integrated Approach to Pain and Opioid Use in Hemodialysis Patients: The Hemodialysis Opioid Prescription Effort (HOPE) Consortium - Clinical Centers (U01 Clinical Trial Required)
Federal Agency Name: National Institutes of Health (HHS-NIH11)
Grant Categories: Food and Nutrition Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-DK-18-030
Type of Funding: Cooperative Agreement
CFDA Numbers: 93.847, 93.866
CFDA Descriptions: Information not provided
Current Application Deadline: March 27th, 2019
Original Application Deadline: March 27th, 2019
Posted Date: December 10th, 2018
Creation Date: December 10th, 2018
Archive Date: May 2nd, 2019
Total Program Funding:
Maximum Federal Grant Award: $500,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Last Updated: December 10th, 2018
Applicants Eligible for this Grant
State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Link to Full Grant Announcement
http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-18-030.html
Grant Announcement Contact
NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants
Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogen...
Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)
Continuous Ketone Monitoring for the Safe Use of Sodium-glucose Cotransporter-2 Inhibitors...
NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Requ...
NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements...
Proteomic and Metabolomic Approaches to Diagnose Diabetes and Pre-Diabetes
Molecular Therapy Core Centers
Pilot and Feasibility Program in Human Islet Biology
More Grants from the National Institutes of Health
Feasibility of Novel Diagnostics for TB in Endemic Countries (FEND for TB) (R01 Clinical ...
Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Mino...
Strategies for Controlled Release of HIV Vaccines (SCORE-H) (R01 Clinical Trial Not Allowe...
NINDS Program Project Grant (P01 Clinical Trial Optional)
Centers for Research in Emerging Infectious Diseases (CREID) Network (U01 Clinical Trial N...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024 FederalGrants.com